A test that measures the expression levels of 58 genes in oestrogen receptor-positive breast cancers can effectively differentiate between patients who are at higher and lower risk for having their cancer recur elsewhere in the body more than five years after diagnosis, researchers report.
[More]
More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.
[More]
Triple negative breast cancer (TNBC) is a type of cancer that has none of the three markers that are currently used for targeted chemotherapy. These markers are estrogen receptor (ER), progesterone receptor (PR) and HER2.
[More]
ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria.
[More]
New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.
[More]
A study of older patients with advanced head and neck cancers has found that where they were treated significantly influenced their survival.
[More]
PDL BioPharma, Inc. (PDL) today reported financial results for the fourth quarter and full year ended December 31, 2012.
[More]
Novian Health, developer of Novilase Breast Therapy, announced today that it has successfully completed a funding round totaling $11 million.
[More]
Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.
[More]
A new tool that could allow for faster, more comprehensive testing of brain tissue during surgery successfully identified the cancer type, grade and tumor margins in five brain surgery patients, according to a Purdue University and Brigham and Women's Hospital study.
[More]
The latest generation of genomic tests for breast cancer can improve physicians' ability to diagnose the disease and more precisely tailor each patient's treatment, according to a study being presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The study examined the first commercially available genomic tests to determine the molecular subtype of a breast cancer tumor.
[More]
A team of brain cancer researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has effectively treated brain tumor cells using a unique combination of diet and radiation therapy.
[More]
Patients with rectal cancer managed conservatively following a complete response to chemoradiotherapy achieve similar rates of disease control as those who undergo rectal resection, research shows.
[More]
Findings from the AVANT trial do not support the use of bevacizumab in patients receiving oxaliplatin-based chemotherapy for resected stage III or high-risk stage II colon carcinoma.
[More]
At the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) held this weekend in Barcelona, Spain, specialists from radiology, urology, medical oncology and pathology said that new developments and research are already underway but benefits to patients would take some time due to the need for clinical trials, the high cost of funding research and the ability of cancer experts to efficiently take advantage of new insights and approaches, among other challenges.
[More]
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin-), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.
[More]
The increased expression of a leukotriene receptor and a glucocorticoid receptor may contribute to the development of nasal polyposis, report researchers.
[More]
Patients who are likely to experience disease recurrence after undergoing hepatectomy for hepatocellular carcinoma can be identified by factors that are available preoperatively, indicate the results of a Hong Kong study.
[More]
Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.
[More]
Before suggesting surgery as palliative therapy for patients with recurrent glioblastoma, physicians should consider the impact of morbidities on quality of life, suggest researchers from Italy.
[More]